Clearmind Medicine (CMND) News Today → Do This Today BEFORE Biden Wins in November (From Stansberry Research) (Ad) Free CMND Stock Alerts $1.40 -0.10 (-6.67%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineClearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Productglobenewswire.com - May 10 at 8:24 AMWhy Clearmind Medicine Stock Is Moving Highermsn.com - May 7 at 4:12 PMClearmind Medicine Inc.: Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatmentfinanznachrichten.de - May 7 at 11:12 AMClearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatmentglobenewswire.com - May 7 at 7:46 AMClearmind Medicine (NASDAQ:CMND) Shares Down 0.8% americanbankingnews.com - May 3 at 2:54 AMClearmind Medicine Inc.: Clearmind Applies to Cease Being a Reporting Issuer in Canadafinanznachrichten.de - May 1 at 9:06 AMClearmind Applies to Cease Being a Reporting Issuer in Canadaglobenewswire.com - April 30 at 4:15 PMClearmind signs agreement for psychedelic compounds for mental disorders treatmentmsn.com - April 17 at 10:46 AMClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disordersfinance.yahoo.com - April 17 at 10:46 AMClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disordersglobenewswire.com - April 17 at 7:49 AMClearmind Medicine advances trial for alcohol use disorder treatmentuk.investing.com - April 11 at 12:11 AMClearmind Medicine Inc.: Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disordersfinanznachrichten.de - April 10 at 9:10 AMClearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disordersglobenewswire.com - April 10 at 7:17 AMClearmind Medicine Inc.: Clearmind Medicine CEO Issues Letter to Shareholdersfinanznachrichten.de - April 9 at 9:46 AMClearmind Medicine CEO Issues Letter to Shareholdersglobenewswire.com - April 9 at 8:07 AMClearmind Medicine files tenth patent for depression treatmentuk.investing.com - March 29 at 3:25 PMSciSparc Ltd: SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depressionfinanznachrichten.de - March 27 at 10:19 AMClearmind Medicine Inc.: Clearmind Medicine Announces International Patent Application for Preventing and Treating Depressionfinanznachrichten.de - March 27 at 10:19 AMClearmind Medicine Announces International Patent Application for Preventing and Treating Depressionglobenewswire.com - March 27 at 9:12 AMBreakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in Chinaglobenewswire.com - March 19 at 7:55 AMClearmind Medicine Inc.: Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchangefinanznachrichten.de - March 13 at 9:12 PMClearmind Medicine Inc.: Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trialfinanznachrichten.de - March 13 at 4:11 PMClearmind Medicine receives nod for delisting of shares from Canadian Securities Exchangemsn.com - March 13 at 4:11 PMClearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trialglobenewswire.com - March 13 at 8:14 AMClearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchangeglobenewswire.com - March 13 at 7:30 AMPodcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviorsmsn.com - March 12 at 5:36 PMEXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compoundsmsn.com - February 27 at 8:59 AMClearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compoundsglobenewswire.com - February 27 at 7:58 AMClearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorderglobenewswire.com - February 23 at 7:06 AMClearmind Medicine Stock (NASDAQ:CMND), Quotes and News Summarybenzinga.com - February 22 at 7:39 PMNext-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patentsbenzinga.com - February 21 at 12:04 PMWhat's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock?msn.com - February 20 at 4:01 PMClearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compoundsfinance.yahoo.com - February 20 at 10:18 AMSciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compoundsfinance.yahoo.com - February 20 at 10:18 AMClearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compoundsglobenewswire.com - February 20 at 7:14 AMClearmind Medicine receives Patent Approval in China for treatment of binge behavioursproactiveinvestors.com - February 14 at 4:04 PMClearmind Medicine Inc (CWY0.MU)ca.finance.yahoo.com - February 10 at 3:48 PMClearmind Medicine Inc.: Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in Chinafinanznachrichten.de - February 5 at 4:01 PMClearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in Chinafinance.yahoo.com - February 5 at 10:59 AMClearmind stock rallies on cocaine addiction treatment updatemsn.com - February 1 at 2:48 PMClearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Centerfinance.yahoo.com - February 1 at 2:48 PMAegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc.finanznachrichten.de - January 16 at 3:36 PMClearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placementfinance.yahoo.com - January 16 at 3:36 PMAegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)finance.yahoo.com - January 16 at 3:36 PMClearmind Medicine Shares Drop 45% After Pricing of Direct Offeringmarketwatch.com - January 11 at 2:06 PMWhy Clearmind Medicine (CMND) Shares Are Nosedivingmsn.com - January 11 at 2:06 PMClearmind Medicine looks to raise $2.4 million through private placementmsn.com - January 11 at 2:06 PMWhy Is Clearmind Medicine (CMND) Stock Down 24% Today?investorplace.com - January 11 at 11:02 AMClearmind Medicine Inc.: Clearmind Medicine Completed Type A Meeting with the FDAfinanznachrichten.de - January 10 at 11:20 AMClearmind Medicine Shares Rise 51% After Type A FDA Meetingmarketwatch.com - January 10 at 11:20 AM Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market. Click here to get instant access to the guide CMND Media Mentions By Week CMND Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMND News Sentiment▼0.750.52▲Average Medical News Sentiment CMND News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMND Articles This Week▼62▲CMND Articles Average Week Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BPTH News Today GLMD News Today PXMD News Today QLGN News Today DRMA News Today ALLR News Today PRFX News Today ATNF News Today SLRX News Today CNSP News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMND) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
